Unknown

Dataset Information

0

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis.


ABSTRACT: Sarcopenia is a well-known complication of chronic liver disease (CLD), and it is almost always observed in patients with cirrhosis, at least in those with decompensated disease. Since nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is becoming the leading cause of end-stage liver disease, a new scenario characterized by the frequent coexistence of NAFLD, obesity, and sarcopenia is emerging. Although it is not yet resolved whether the bidirectional relationship between sarcopenia and NAFLD subtends causal determinants, it is clear that the interaction of these two conditions is associated with an increased risk of poor outcomes. Notably, during the course of CLD, deregulation of the liver-muscle-adipose tissue axis has been described. Unfortunately, owing to the lack of properly designed studies, specific therapeutic guidelines for patients with sarcopenia in the context of NAFLD-related CLD have not yet been defined. Strategies aimed to induce the loss of fat mass together with the maintenance of lean body mass seem most appropriate. This can be achieved by properly designed diets integrated with specific nutritional supplementations and accompanied by adequate physical exercise. Future studies aiming to add to the knowledge of the correct assessment and approach to sarcopenia in the context of NAFLD-related CLD are eagerly awaited.

SUBMITTER: Gallo P 

PROVIDER: S-EPMC10899871 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis.

Gallo Paolo P   Flagiello Valentina V   Falcomatà Andrea A   Di Pasquale Giulia G   D'Avanzo Giorgio G   Terracciani Francesca F   Picardi Antonio A   Vespasiani-Gentilucci Umberto U  

Journal of clinical and translational hepatology 20240126 3


Sarcopenia is a well-known complication of chronic liver disease (CLD), and it is almost always observed in patients with cirrhosis, at least in those with decompensated disease. Since nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is becoming the leading cause of end-stage liver disease, a new scenario characterized by the frequent coexistence of NAFLD, obesity, and sarcopenia is emerging. Although it is not yet resol  ...[more]

Similar Datasets

| S-EPMC7132022 | biostudies-literature
| S-EPMC9062842 | biostudies-literature
| S-EPMC8573524 | biostudies-literature
| S-EPMC7716119 | biostudies-literature
| S-EPMC8170238 | biostudies-literature
| S-EPMC6484583 | biostudies-literature
| S-EPMC9303958 | biostudies-literature
| S-EPMC10107331 | biostudies-literature
| S-EPMC6136489 | biostudies-literature
| S-EPMC10850360 | biostudies-literature